Vitamin B1: Benefits, Evidence, Dosing & Side Effects

Overview

Vitamin B1, also known as thiamine, is a water-soluble essential vitamin that serves as a critical cofactor in energy metabolism and neurological function. Unlike fat-soluble vitamins that accumulate in body tissues, B1 must be obtained regularly through diet or supplementation since the body cannot store significant amounts. While thiamine deficiency is relatively rare in developed nations, it remains a serious public health concern in populations with malnutrition, alcohol use disorder, or those undergoing bariatric surgery.

Thiamine's primary clinical applications include preventing and treating deficiency states such as beriberi and Wernicke-Korsakoff syndrome—conditions characterized by severe neurological impairment. Beyond deficiency treatment, high-dose thiamine formulations (particularly benfotiamine and TTFD) are increasingly investigated for managing diabetic neuropathy, fatigue syndromes, and metabolic dysfunction. This article reviews the current evidence for thiamine's benefits across multiple health domains, along with practical dosing and safety information.

How It Works: Mechanism of Action

Thiamine's biological activity depends on its conversion to thiamine pyrophosphate (TPP), a coenzyme that participates in critical metabolic pathways. Once absorbed orally or via injection, thiamine is phosphorylated intracellularly to TPP, which then functions as an essential cofactor for several key enzymes:

• Pyruvate dehydrogenase: Converts pyruvate to acetyl-CoA, a central step in ATP production
• Alpha-ketoglutarate dehydrogenase: Critical enzyme in the citric acid cycle for energy generation
• Transketolase: Key enzyme in the pentose phosphate pathway, supporting nucleotide and antioxidant synthesis

Beyond energy metabolism, TPP is essential for acetylcholine synthesis—a neurotransmitter critical for cognitive function and muscle contraction—and for maintaining the integrity of myelin sheaths that insulate peripheral and central nerves. Without adequate thiamine, cells with high metabolic demands (particularly neurons and cardiac myocytes) cannot generate sufficient ATP, leading to oxidative stress, energy depletion, and functional impairment.

This mechanism explains why thiamine deficiency manifests primarily as neurological and cardiac symptoms rather than generalized weakness. The brain and nervous system depend disproportionately on thiamine-dependent energy production, making them especially vulnerable to deficiency.

Evidence by Health Goal

Fat Loss

Evidence Tier: 1 (No Proven Efficacy)

Vitamin B1 supplementation has no demonstrated efficacy for fat loss. While thiamine is essential for carbohydrate metabolism, supplementation does not improve weight loss outcomes in humans. The limited research in this area focuses on preventing thiamine deficiency in bariatric surgery patients, not on achieving fat loss.

In one randomized controlled trial of obese type 2 diabetic patients (n=82), combined supplementation with thiamine, alpha-lipoic acid, and carnosine reduced fasting glucose (135.7 to 126.5 mg/dL) and HbA1c (8.3% to 6.03%). However, the same intervention increased fasting insulin (3.6 to 6.8 μIU/mL) and HOMA-IR, suggesting no net metabolic benefit despite improved glycemic markers.

Bottom line: B1 supplementation is not a fat loss tool and should not be used for weight management.

Muscle Growth

Evidence Tier: 1 (No Proven Efficacy)

There is no credible evidence that thiamine supplementation improves muscle growth in humans. While thiamine deficiency causes muscle atrophy as part of severe neurological disease, correcting deficiency is treatment of a disease state, not performance enhancement.

Research on thiamine in muscular contexts has focused on disease states. In critically ill patients, high-dose thiamine improved lactate clearance and mortality outcomes in septic shock (retrospective cohort of 123 treated vs 246 control patients), but this demonstrates metabolic benefits in serious illness, not muscle-building potential.

Bottom line: B1 has no direct role in muscle protein synthesis or growth in adequately nourished individuals.

Injury Recovery

Evidence Tier: 1 (No Proven Efficacy)

Vitamin B1 has not been shown to improve injury recovery in humans. While thiamine deficiency causes severe neurological complications that resolve with treatment, this represents correction of pathology rather than enhancement of recovery processes.

In a small study of burn patients (n=6), thiamine supplementation significantly increased serum thiamine concentrations and decreased pyruvate and lactate levels. However, no functional recovery outcomes were measured, and the study was too small to draw meaningful conclusions about injury recovery benefits.

Bottom line: Current evidence does not support B1 supplementation for accelerating injury recovery.

Joint Health

Evidence Tier: 1 (No Proven Efficacy)

No evidence demonstrates that vitamin B1 improves joint health. Available literature focuses on thiamine's role in carbohydrate metabolism and neurological function, with no studies specifically examining effects on joint structure or function.

Bottom line: B1 is not indicated for joint health support.

Anti-Inflammation

Evidence Tier: 3 (Probable Benefit)

Vitamin B1 shows probable benefit for reducing inflammation and improving outcomes in sepsis, supported by multiple human studies with consistent positive findings. However, evidence is limited by small sample sizes and lacks large-scale randomized trials.

A large observational study (n=11,553 sepsis patients) with propensity score matching found that thiamine supplementation reduced ICU mortality by 20% (HR 0.80, 95% CI 0.70-0.93). Additionally, a randomized controlled trial (n=88) demonstrated that thiamine significantly improved ICU-free days in septic shock patients (median 22.5 days vs 0.0 days, P<0.01).

These findings suggest thiamine may have genuine anti-inflammatory or immunomodulatory effects in acute illness contexts, though the mechanisms remain incompletely understood.

Bottom line: B1 shows promise for sepsis outcomes but evidence is limited to acute care settings.

Cognition

Evidence Tier: 2 (Weak Efficacy)

Thiamine deficiency is clearly linked to severe cognitive impairment, particularly in alcohol use disorder and in Wernicke-Korsakoff syndrome. However, evidence that supplementation improves cognition in people with adequate thiamine status is weak and inconsistent.

In a striking observational case series, 9 of 10 dialysis patients with unexplained encephalopathy (confusion, dementia, and myoclonus) showed marked clinical improvement after receiving IV thiamine, with 9 achieving full recovery. This demonstrates thiamine's critical role in preventing cognitive decline from deficiency.

Conversely, in cognitively normal young adults (n=120, randomized controlled trial), 50 mg/day thiamine for 2 months improved reaction times and self-reported alertness but did NOT improve memory performance, suggesting benefits are limited to symptom perception rather than objective cognitive enhancement.

Bottom line: B1 prevents cognitive decline from deficiency but does not enhance cognition in adequately nourished individuals.

Mood & Stress

Evidence Tier: 2 (Modest Efficacy)

Vitamin B1 supplementation shows modest benefits for mood and stress-related symptoms in limited human trials. One well-designed randomized trial demonstrated meaningful improvements in psychological well-being, though evidence remains sparse overall.

In a randomized controlled trial of 120 young women, 50 mg thiamine daily for 2 months increased reports of being "clearheaded, composed, and energetic" with faster reaction times compared to placebo, though no effect on memory was observed.

A more robust effect was seen in women with polycystic ovary syndrome (n=64, randomized controlled trial) given 300 mg thiamine daily for 4 weeks. This group showed significant improvements in anxiety/insomnia (P<0.001), social dysfunction (P=0.028), and severe depression (P<0.001) on general health questionnaires compared to placebo.

Bottom line: B1 may modestly improve mood and stress symptoms, particularly in specific populations, but evidence is limited.

Sleep

Evidence Tier: 2 (Weak Efficacy)

Vitamin B1 shows a trend toward improving sleep in one randomized controlled trial in elderly patients with subclinical deficiency, but evidence is limited to a single small trial with borderline statistical significance.

Elderly participants (n=35, randomized controlled trial) given 10 mg/day thiamine for 3 months showed a trend toward improved sleep quality (P=0.07), though this did not reach statistical significance.

A separate randomized controlled trial in women with PCOS (n=64) given 300 mg/day for 4 weeks demonstrated significant reductions in insomnia scores (P<0.001), suggesting benefits may be population-specific.

Bottom line: B1 may help sleep in specific populations but lacks robust general population evidence.

Longevity

Evidence Tier: 2 (Weak Efficacy)

Vitamin B1 deficiency is associated with cognitive decline and neurodegenerative processes, but evidence for B1 supplementation improving longevity or age-related outcomes in humans is lacking. Only mechanistic and observational data exist.

In an observational study of 188 women, those in the lowest serum B1 tertile had a 3.73-fold increased dementia risk compared to those in the highest tertile (95% CI: 1.52-9.16). No significant association was found in men, suggesting sex-specific effects. In cellular and mouse models, B1 deficiency increased beta-amyloid accumulation through enhanced BACE1 activity, while thiamine supplementation reversed this effect.

Bottom line: B1 may support cognitive longevity but human longevity data are absent.

Immune Support

Evidence Tier: 2 (Plausible but Limited)

Vitamin B1 shows plausible immune-enhancing mechanisms in animal and cell culture studies, but human evidence is limited to observational data and one small mechanistic study. No rigorous randomized trials demonstrate immune benefits in adequately nourished individuals.

In human peripheral blood mononuclear cells, thiamine enhanced CD8+ T cell activation, cytotoxic function, and mitochondrial fitness. In mouse models, thiamine supplementation reversed PTSD-induced tumor promotion by restoring CD8+ immune function. Additionally, benfotiamine significantly reduced pro-inflammatory cytokines (TNF-α, IL-6, iNOS) and increased anti-inflammatory IL-10 in stimulated mouse microglial cells.

Bottom line: B1 has theoretical immune benefits but lacks human clinical trial evidence.

Energy

Evidence Tier: 2 (Weak Efficacy)

Vitamin B1 is essential for energy metabolism and shows promise in specific deficiency conditions, but evidence for improving energy in healthy or non-deficient individuals is minimal. Most human data involve treating deficiency states rather than enhancing performance.

Notably, one randomized controlled trial (n=12) found that high-dose thiamine (300 mg/day for 6 weeks) in hyperglycemic patients actually decreased resting energy expenditure by 48.5 kcal/day (1478.93 vs 1526.40 kcal/d, p=0.02)—opposite to expected direction.

More promising was a study in 16 male athletes where thiamine supplementation (100 mg/day for 3 days) significantly decreased subjective fatigue complaints shortly after exercise, with suppressed blood glucose increase during activity.

Bottom line: B1 may modestly reduce fatigue in athletes but does not reliably increase energy in general populations.

Gut Health

Evidence Tier: 1 (No Proven Efficacy)

Vitamin B1 is essential for preventing deficiency-related diseases but does not demonstrate active improvement of gut health in healthy individuals. Evidence focuses on correcting deficiency in at-risk populations.

Thiamine deficiency is present in 39.7% of critically ill ICU patients at admission and associates with gastrointestinal pathology and recent surgery. Additionally, 16.5% of obese patients undergoing bariatric surgery screening showed clinical thiamine deficiency with gastrointestinal manifestations.

Bottom line: B1 corrects deficiency-related GI problems but does not improve gut health in non-deficient individuals.

Heart Health

Evidence Tier: 3 (Probable Benefit but Inconsistent)

Vitamin B1 supplementation shows probable but inconsistent benefits for heart health, particularly in heart failure patients. While multiple studies suggest potential improvements in left ventricular ejection fraction (LVEF), recent meta-analyses reveal conflicting results.

An earlier meta-analysis (n=38 randomized trials) showed a 3.28% improvement in LVEF with thiamine versus placebo (95% CI: 0.64-5.93%, p<0.05). However, a recent large meta-analysis (n=274 patients, 7 randomized trials) found NO significant improvement in LVEF with thiamine versus placebo (1.653%, 95% CI: -1.098 to 4.405, p=0.239).

Bottom line: B1 may support heart function but evidence is mixed and inconsistent.

Liver Health

Evidence Tier: 2 (Weak Efficacy)

Vitamin B1 is essential for liver function and is depleted in chronic liver disease, with supplementation restoring thiamine-dependent enzyme activity. However, evidence of direct improvement to liver function outcomes in humans is limited.

Biochemical thiamine deficiency was found in 58% of chronic liver disease patients, and 200 mg/day supplementation restored thiamine pyrophosphate to normal in all cases. Additionally, 40% of hyperemesis gravidarum patients with thiamine-deficiency-related Wernicke's encephalopathy showed abnormal liver function tests (AST >100 U/L), which improved with thiamine therapy.

Bottom line: B1 corrects deficiency-related liver dysfunction but efficacy for improving liver health outcomes is unproven.

Hormonal Balance

Evidence Tier: 2 (Weak Efficacy)

Vitamin B1 shows plausible effects on glucose metabolism in small studies, but evidence is limited to 2 randomized trials with small samples (n=12 each). Efficacy for hormonal health in non-deficient individuals is not proven.

High-dose thiamine (300 mg/day for 6 weeks) reduced 2-hour plasma glucose by 1.11 mmol/L compared to baseline in hyperglycemic patients (p=0.004, n=12). Fasting insulin and HOMA-IR increased significantly in the placebo group but remained stable in the thiamine group, suggesting B1 may prevent glucose deterioration rather than actively improve glycemic control.

Bottom line: B1 may stabilize glucose metabolism but evidence is limited and inconsistent.

Sexual Health

Evidence Tier: 2 (Weak Efficacy)

One human randomized controlled trial shows vitamin B1 may improve general health and psychological symptoms in women with polycystic ovary syndrome, though sexual health outcomes were not directly measured.

Women with PCOS given 300 mg/day for 4 weeks showed significant improvements in overall general health questionnaire scores (P<0.001, n=64) and reduced somatic symptoms (P<0.001). These improvements may indirectly support sexual health through enhanced psychological well-being, but direct sexual function outcomes were not assessed.

Bottom line: B1 may improve psychological well-being in women with PCOS but does not directly address sexual health.

Athletic Performance

Evidence Tier: 2 (Weak Efficacy)

Vitamin B1 shows plausible benefits for athletic performance based on limited human evidence, but efficacy in athletes is not proven. Evidence is restricted to a single human trial with a small sample.

Thiamine supplementation (10 mg/kg for 4 weeks) significantly decreased lactate concentration during 15-60 minutes of exercise compared to placebo in human subjects (n=9). The same intervention decreased ammonia concentration during 15-60 minutes of exercise and recovery.

Bottom line: B1 may reduce lactate and ammonia during exercise but evidence is too limited for definitive conclusions.

Dosing Protocols

Oral Dosing

Standard oral thiamine supplementation ranges from 50-300 mg once daily. Most supplemental forms are well-absorbed at these doses. Higher-dose benfotiamine (a fat-soluble thiamine derivative) and TTFD (thiamine tetrahydrofurfuryl disulfide) formulations are increasingly used therapeutically for diabetic neuropathy and may range up to 300 mg daily, though optimal dosing protocols remain unclear.

Injection (Clinical Settings)

Intravenous or intramuscular thiamine is used in medical settings for acute deficiency states and is typically dosed at 100-500 mg once daily for acute deficiency, then tapered to maintenance dosing (typically weekly injections) following clinical improvement. Parenteral administration achieves higher tissue concentrations rapidly and is reserved for severe deficiency presentations such as Wernicke encephalopathy or beriberi.

Deficiency Prevention

For preventing deficiency in at-risk populations (post-bariatric surgery, chronic diarrhea, dialysis), lower maintenance doses of 10-25 mg daily are often sufficient once acute deficiency is corrected.

Side Effects & Safety

Safety Profile

Thiamine has an excellent safety profile as a water-soluble vitamin. Excess thiamine is readily